Skip to main content
. 2021 Jun;10(6):2478–2492. doi: 10.21037/tau-21-445

Figure 8.

Figure 8

Relationship between risk scores and drug sensitivity. Sorafenib (A), sunitinib (B), temsirolimus (C), cisplatin (D), and gemcitabine (E).